Altimmune Inc (ALT) 13F Holdings Overview (Q2 2026)

ALT ranks #2878 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

211 institutions disclose a position in ALT, but none treat it as a major bet — even Trails Edge Capital Partners, LP, its most concentrated holder, allocates just 1.3% of its own portfolio to it.

BlackRock has added to its ALT position for two straight quarters, increasing it by $26.9M to reach $62.0M today.

Jane Street Group, LLC has trimmed its ALT position for two straight quarters, cutting it by $6.6M while still holding $841.5K.

ALT is up 6.1% today, and institutions have been net buyers of $262.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ALT reported a net loss of $91.8M over the trailing twelve months.

• Not yet profitable — net loss of $91.8M over the trailing twelve months
• Revenue grew 105.0% year over year
• Net income declined year over year, from -$87.7M to -$91.8M
• Operating cash flow was negative, using $67.5M in cash
• Current ratio of 18.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.24x equity — within a conventional range